THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCE

 描述（由申请人提供）：NCTN的肿瘤临床试验联盟（Alliance）代表了三个前NCI资助的癌症合作组织（ACOSOG，CALGB和NCCTG）的合并。结合起来，这些群体及其相关的生物储存库代表了无与伦比的专业知识，机构基础设施和高质量，从几十年的癌症治疗试验中收集的密集注释的患者生物标本资源。联盟生物储存库和生物样本资源（ABBR）的科学使命是通过四个具体目标支持联盟、NCTN和更广泛的癌症研究界的活动，这四个目标是：1）在生物样本采购、跟踪、处理、质量保证、储存和分发方面前瞻性地支持联盟和NCTN范围内的临床癌症试验。ABBR将开发简化生物标本采集的方法，并支持在治疗试验背景下收集用于基于基因组和蛋白质组学的生物标志物研究的新型生物标本类型; 2）为二级相关科学研究提供高质量，密集注释的生物标本资源，这些研究旨在进行具有高度临床影响的生物标志物验证。ABBR将与其他NCTN生物储存库，NCTN生物标本“前门服务”和NCTN导航工具合作，提供可能适合NCTN小组以及更广泛的癌症研究社区内提出的二级相关科学研究的生物标本清单。它还将与其他NCTN成员和NCI合作，创建一个高效透明的流程，用于审查、批准和执行此类请求，以加快将候选生物标志物转化为具有临床实用性的癌症诊断; 3）通过积极参与NCTN集团银行委员会（GBC），为NCTN生物银行业务提供科学领导。ABBR将通过积极参与GBC会议、小组委员会活动和工作产品，继续致力于协调和改进生物库最佳实践; 4）为NCTN以外的生物库工作提供专业知识和基础设施支持，包括NCI的实验治疗药物临床试验网络（ETCTN）和社区肿瘤学研究计划（NCORP）。通过创建生物库站点的联合基础设施和统一的信息学平台来跟踪生物样本，ABBR特别准备与其他NCI项目合作，无论何时生物库或生物样本资源需要特定的转化癌症研究工作。

 DESCRIPTION (provided by applicant): The NCTN's Alliance for Clinical Trials in Oncology (Alliance) represents a merger of three former NCI-funded cancer cooperative groups (ACOSOG, CALGB, and NCCTG). Combined, these groups and their associated biorepositories represent an unequaled resource of expertise, institutional infrastructure, and high quality, densely annotated patient biospecimens collected from several decades of cancer therapeutic trials. The scientific mission of the Alliance Biorepository and Biospecimen Resource (ABBR) is to support the activities of the Alliance, the NCTN, and the broader cancer research community through four specific aims, which are: 1) To prospectively support Alliance and NCTN-wide clinical cancer trials with respect to biospecimen procurement, tracking, processing, quality assurance, storage, and distribution. The ABBR will develop approaches to streamline biospecimen collection and support the collection of novel biospecimen types for genomic- and proteomic-based biomarker studies in the context of therapeutic trials; 2) To provide a resource of high quality, densely annotated biospecimens for secondary correlative science studies directed toward biomarker validation with high clinical impact. The ABBR will work with other NCTN biorepositories, the NCTN Biospecimen `Front Door Service', and the NCTN Navigator tool to provide inventories of biospecimens that may be suitable for secondary correlative science studies proposed both within the NCTN groups as well as the broader cancer research community. It will also work with other NCTN members and NCI to create an efficient and transparent process for reviewing, approving, and executing such requests so as to speed the translation of candidate biomarkers to cancer diagnostics with clinical utility; 3) To provide scientific leadership to the NCTN biobanking enterprise, by active participation in the NCTN Group Banking Committee (GBC). The ABBR will continue its outstanding commitment to harmonizing and improving biobanking Best Practices by active participation in GBC meetings, subcommittee's activities, and work products, and; 4) To provide expertise and infrastructure support for biobanking efforts beyond the NCTN, including NCI's Experimental Therapeutics Clinical Trials Network (ETCTN) and the Community Oncology Research Program (NCORP). By creating a federated infrastructure of biorepository sites and a unifying informatics platform for tracking biospecimens across them, the ABBR is uniquely poised to collaborate with other NCI programs, whenever biorepository or biospecimen resources are required for specific translational cancer research efforts.